Management of Highly Active Anti-retroviral Therapy-related Hyperlipidemia Among HIV-infected Patients in Taiwan
Management of Highly Active Anti-retroviral Therapy-related Hyperlipidemia Among HIV-infected Patients in Taiwan
1. Written informed consent must be obtained before any study specific procedures are
 undertaken.

 2. The process of the experiment (brief describe) The patients must come back for follow
 during 4 to 12 weeks after starting the new therapy. The investigators will follow the
 patients' lipid profile and any side effects and stop the observation till 36 months
 after starting the new therapy. The serum level of HIV-VL, CD4, GOT, GPT, triglyceride,
 cholesterol, HDL-cholesterol, and LDL-cholesterol will be checked every 3 months. The
 patients' chart and all data will be delinked to protect the patients' right and
 privacy.
Inclusion Criteria:

 -  HIV-infected patients who receive HAART therapy but have metabolic side effects.

 -  Age over 20 years old

 Exclusion Criteria:

 -  Abnormal liver function: GOT or GPT 5 times over normal upper limit